We have gathered all the information for you in one convenient spot, but please keep in mind that these are subject to change. We do our best to keep everything updated, but something might be out of ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a deal. On Sunday ...

$ 93.76 1.34 1.46% ...

After hours: November 29 at 4:51 PM EST Loading Chart for GILD ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the United States, 4.5 million adults live with diagnosed liver disease. For decades, Gilead Sciences has been a pioneer in the treatment of liver diseases, impacting patients worldwide ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV prevention in vulnerable populations, Gilead’s anti-diversion clause to make the ...

**NM signifies a non meaningful value. A dash signifies the data is not available.